bioAffinity Technologies faces Nasdaq delisting risk after shares trade below $1 bid-price minimum

Reuters2026/07/31 21:15

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

bioAffinity Technologies received a Nasdaq staff determination for failing the $1 minimum bid price rule, with shares below $1 for 30 sessions.
Nasdaq denied the standard 180-day cure period because of a 1-for-30 reverse split on Sept. 19, 2025.
An appeal due Aug. 6, 2026 would stay delisting pending a Nasdaq hearings panel decision.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-035672), on July 31, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

bioAffinity Technologies faces Nasdaq delisting risk after shares trade below $1 bid-price minimum

You may also like

Crypto prices